Nicholas Lintzeris

Summary

Country: Australia

Publications

  1. ncbi Benzodiazepines, methadone and buprenorphine: interactions and clinical management
    Nicholas Lintzeris
    Sydney South West Area Health Service and University of Sydney, Sydney, Australia
    Am J Addict 19:59-72. 2010
  2. ncbi Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation
    Louisa Degenhardt
    National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
    Med J Aust 191:161-5. 2009
  3. ncbi Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project
    Erol Digiusto
    National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia
    Addict Behav 30:443-56. 2005
  4. ncbi Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions
    Courtney L Breen
    National Drug and Alcohol Research Centre, University of New South Wales, NSW 2052, Sydney, Australia
    Drug Alcohol Depend 71:49-55. 2003
  5. ncbi The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic
    Parameswaran Ramasamy
    Drug Health Service, Sydney South West Area Health Service, Sydney, Australia
    Addiction 105:329-34. 2010
  6. ncbi Prescription of heroin for the management of heroin dependence: current status
    Nicholas Lintzeris
    Sydney South West Area Health Service, Drug Health Services, Royal Prince Alfred Hospital, Camperdown, Sydney, New South Wales, Australia
    CNS Drugs 23:463-76. 2009

Collaborators

Detail Information

Publications6

  1. ncbi Benzodiazepines, methadone and buprenorphine: interactions and clinical management
    Nicholas Lintzeris
    Sydney South West Area Health Service and University of Sydney, Sydney, Australia
    Am J Addict 19:59-72. 2010
    ..An overview of treatment approaches for managing BZD use in this population is presented, including strategies for minimizing abuse and addressing BZD dependence...
  2. ncbi Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation
    Louisa Degenhardt
    National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
    Med J Aust 191:161-5. 2009
    ..Comparison was made with injecting of two other opioid substitution treatment medications, methadone and buprenorphine (BPN); severe harms have been documented after injection of the latter...
  3. ncbi Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project
    Erol Digiusto
    National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia
    Addict Behav 30:443-56. 2005
    ....
  4. ncbi Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions
    Courtney L Breen
    National Drug and Alcohol Research Centre, University of New South Wales, NSW 2052, Sydney, Australia
    Drug Alcohol Depend 71:49-55. 2003
    ..Buprenorphine is used in the treatment of opioid dependence. Due to its pharmacology, the transfer from methadone to buprenorphine may precipitate withdrawal symptoms...
  5. ncbi The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic
    Parameswaran Ramasamy
    Drug Health Service, Sydney South West Area Health Service, Sydney, Australia
    Addiction 105:329-34. 2010
    ..This study examines the completion rates of a HBV vaccination schedule and seroconversion in a group of patients in methadone maintenance treatment...
  6. ncbi Prescription of heroin for the management of heroin dependence: current status
    Nicholas Lintzeris
    Sydney South West Area Health Service, Drug Health Services, Royal Prince Alfred Hospital, Camperdown, Sydney, New South Wales, Australia
    CNS Drugs 23:463-76. 2009
    ....